Zoetis Inc. $ZTS Shares Sold by Crestwood Advisors Group LLC

Key Points

• Crestwood Advisors Group LLC trimmed its Zoetis stake by 41.2%, selling 80,815 shares and ending the quarter with 115,176 shares worth about $14.49 million.
• Zoetis missed Q1 estimates (EPS $1.53 vs. ~ $1.60) and set FY‑2026 guidance of $6.85–7.00 EPS and $9.7–10.0B revenue, with management citing weaker U.S. pet demand and generic competition—news that triggered a sell‑off and left analysts split (consensus: "Hold", target ≈ $151.75).

Crestwood Advisors Group LLC cut its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 41.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 115,176 shares of the company's stock after selling 80,815 shares during the period. Crestwood Advisors Group LLC's holdings in Zoetis were worth $14,492,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Global Wealth Strategies & Associates acquired a new stake in Zoetis in the 4th quarter worth approximately $25,000. Lodestone Wealth Management LLC acquired a new stake in Zoetis in the 4th quarter worth approximately $30,000. KERR FINANCIAL PLANNING Corp acquired a new stake in Zoetis in the 3rd quarter worth approximately $31,000. Holos Integrated Wealth LLC acquired a new stake in Zoetis in the 4th quarter worth approximately $32,000. Finally, Board of the Pension Protection Fund acquired a new stake in Zoetis in the 4th quarter worth approximately $38,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

NYSE:ZTS opened at $86.99 on Friday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm has a market cap of $36.59 billion, a price-to-earnings ratio of 14.45, a price-to-earnings-growth ratio of 1.71 and a beta of 0.87. The company has a 50 day moving average price of $118.49 and a 200-day moving average price of $123.70. Zoetis Inc. has a 1-year low of $85.31 and a 1-year high of $172.23.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the firm earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts forecast that Zoetis Inc. will post 7.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ZTS. Wall Street Zen cut shares of Zoetis from a "buy" rating to a "hold" rating in a research note on Saturday, May 2nd. William Blair restated an "outperform" rating on shares of Zoetis in a research note on Monday, March 2nd. BTIG Research restated a "buy" rating and set a $160.00 price objective on shares of Zoetis in a research note on Thursday, February 26th. Bank of America lifted their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a "neutral" rating in a research note on Friday, February 13th. Finally, Leerink Partners restated a "market perform" rating on shares of Zoetis in a research note on Tuesday, March 10th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $151.75.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Livestock and international businesses provided some offset to the U.S. pet weakness, helping limit total company downside and preserving revenue diversification. Quiver Quant: Opinions on Q1
• Positive Sentiment: Some analysts and investors view the sell‑off as an overreaction given Zoetis’s scale, long‑term pet‑humanization trends and its pipeline — creating potential dip‑buy interest from institutions. Quiver Quant: Opinions on Q1
• Neutral Sentiment: Zoetis revised FY‑2026 guidance to EPS $6.85–7.00 and revenue $9.7–10.0B (vs. consensus EPS ~7.03), giving investors updated targets to model into valuations. Zoetis Press Release (PDF)
• Negative Sentiment: Q1 EPS missed expectations ($1.53 vs. $1.61 consensus) and revenue came in light (~$2.26B vs. ~$2.30B est.), triggering the initial sell reaction. Zacks: Q1 miss
• Negative Sentiment: Management cited weaker U.S. companion‑animal demand, price sensitivity among pet owners and lower veterinary visits as the primary drivers of the slowdown — factors that could persist near term and pressure the core domestic business. Benzinga: Weak pet care demand
• Negative Sentiment: Competitive pressure from generics hit legacy products (e.g., Convenia, Cerenia) and strained dermatology/parasiticide growth, raising concerns about near‑term revenue sustainability. Quiver Quant: Competitive pressures
• Negative Sentiment: Market reaction was amplified by heavy trading and negative headlines; coverage and social discussion highlighted the abrupt slowdown and the guidance cut as reasons for a sharp drop in the share price. Fool: Why shares plummeted

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.